Healthcare

Spectral AI Announces Receipt of $1 Million of Financing for Spectral IP, Inc., its Intellectual Property Subsidiary Focused on the Broader Artificial Intelligence Ecosystem

DALLAS, March 19, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence…

1 week ago

HealthLynked Corp Announces Chris Hall as New Chief Technology Officer

NAPLES, Fla., March 19, 2024 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp (OTCQB: HLYK), a leader in healthcare technology innovation,…

1 week ago

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

The proprietary AI-Immunology™ platform brings the potential for a new era in vaccine discovery, design and development using advanced AI…

1 week ago

Repligen Appoints Maggie A. Pax to Board of Directors

WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors…

1 week ago

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting…

1 week ago

SPEVIGO® approved for expanded indications in China and the US

Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as…

1 week ago

Unauthorized Access to Employee Mobile Devices Leads to More Than Half of Organizations Experiencing a Data Breach, New Report Finds

Research conducted by Imprivata and Ponemon Institute finds 28% of IT and IT security practitioners say their organizations can secure…

1 week ago

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients

56% of Participants on Paltusotine Achieved IGF-1 ≤1.0 xULN vs. 5% on Placebo (p<0.0001) Paltusotine was Generally Well-tolerated with No…

1 week ago

Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024

MELBOURNE, Australia and PRINCETON, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company…

1 week ago

Leading in health technology innovation: Philips one of the top patent applicants at European Patent Office

Philips Azurion neuro biplane system Philips CT 5300 system Philips HealthSuite Imaging Philips EPIQ Elite ultrasound system March 19, 2024…

1 week ago